StreetInsider.com News Articles

Form 424B3 LB PHARMACEUTICALS INC

Wed, 22 Jul 2026 08:51:00 -0400

si-local-file:///var/storage/secattach/20260722/26798970.html

Form 424B3 LB PHARMACEUTICALS INC

Wed, 22 Jul 2026 08:51:00 -0400

si-local-file:///var/storage/secattach/20260722/26798970.html

Form 8-K LB PHARMACEUTICALS INC For: Jul 22

Wed, 22 Jul 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260722/26798664.html

Form 8-K LB PHARMACEUTICALS INC For: Jul 22

Wed, 22 Jul 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260722/26798664.html

LB Pharmaceuticals moves up Phase 3 schizophrenia trial readout

Wed, 22 Jul 2026 08:00:43 -0400

LB Pharmaceuticals Inc. (Nasdaq: LBRX) said it now expects to report topline results from its Phase 3 NOVA-2 clinical trial of LB-102 in schizophrenia patients in the first half of 2027, ahead of its prior guidance of the second half of 2027, citing faster-than-expected patient enrollment.

The company said it plans to schedule a pre-NDA meeting with the FDA in the second half of 2027 following the data readout. NOVA-2 is a randomized, double-blind, placebo-controlled trial designed to enroll approximately 460 patients across 25 U.S. sites.

"Enrollment in our pivotal Phase 3 NOVA-2 trial has been more rapid than we expected," said

LB Pharmaceuticals moves up Phase 3 schizophrenia trial readout

Wed, 22 Jul 2026 08:00:43 -0400

"Enrollment in our pivotal Phase 3 NOVA-2 trial has been more rapid than we expected," said

LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia

Wed, 22 Jul 2026 08:00:00 -0400

NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain diseases, today announced that based on enrollment projections, it now expects to report topline results from the pivotal Phase 3 NOVA-2 clinical trial of LB-102 in patients with schizophrenia in the first half of 2027 and to schedule a pre-NDA meeting with the FDA thereafter in the second half of 2027. NOVA-2 is a pivotal Phase 3 multi-center, randomized, double-blind, placebo-controlled

LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia

Wed, 22 Jul 2026 08:00:00 -0400

LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia

Wed, 22 Jul 2026 08:00:00 -0400

LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia

Wed, 22 Jul 2026 08:00:00 -0400

BMO Capital Starts LB Pharmaceuticals Inc (LBRX) at Outperform

Mon, 20 Jul 2026 16:18:17 -0400

(Updated - July 20, 2026 4:18 PM EDT)

BMO Capital analyst Malcolm Hoffman initiates coverage on LB Pharmaceuticals Inc (NASDAQ: LBRX) with a Outperform rating and a price target of $46.00.

The analyst comments "We are initiating coverage of LB Pharmaceuticals at Outperform with a $46 target. While antipsychotic therapies have been well established in schizophrenia treatment, LB Pharma's LB-102 has demonstrated strong initial Ph 2 data that could position the product as differentiated among approved therapies. Fast action efficacy and large effect size demonstrated in Ph 2 increase our confidence in the long-term revenue opportunity and future success of the Ph

BMO Capital Starts LB Pharmaceuticals Inc (LBRX) at Outperform

Mon, 20 Jul 2026 16:18:17 -0400

(Updated - July 20, 2026 4:18 PM EDT)

BMO Capital analyst Malcolm Hoffman initiates coverage on LB Pharmaceuticals Inc (NASDAQ: LBRX) with a Outperform rating and a price target of $46.00.

Form SCHEDULE 13G LB PHARMACEUTICALS INC Filed by: JPMORGAN CHASE & CO

Thu, 16 Jul 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260716/26779573.html

Form SCHEDULE 13G LB PHARMACEUTICALS INC Filed by: JPMORGAN CHASE & CO

Thu, 16 Jul 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260716/26779573.html

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 16:38:00 -0400

NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), today announced that it has granted to Christopher Zergebel, the new Senior Vice President, Clinical Operations of LB Pharmaceuticals, an equity award outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity award was granted on July 10, 2026, pursuant to the “inducement grant” exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Mr. Zergebel entering into employment with LB Pharmaceuticals.

Mr. Zergebel received an option

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 16:38:00 -0400

Mr. Zergebel received an option

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 16:38:00 -0400

Mr. Zergebel received an option

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Fri, 10 Jul 2026 16:38:00 -0400

Mr. Zergebel received an option

Wolfe Research Starts LB Pharmaceuticals Inc (LBRX) at Outperform

Tue, 07 Jul 2026 05:32:33 -0400

Wolfe Research analyst Rudy Li initiates coverage on LB Pharmaceuticals Inc (NASDAQ: LBRX) with a Outperform rating and a price target of $45.00.

The analyst comments "The company is developing LB-102 as a next-gen product improving upon amisulpride, which was an antipsychotic product approved OUS but not in the US. The molecular modification of methylation leads to better brain penetration, potentially enabling lower doses and better safety. LB-102 has established clear POC in a Ph2 schizophrenia study, demonstrating strong efficacy and a favorable safety profile. We believe that LB-102 is a real product that could get approval in schizophrenia, and that

Wolfe Research Starts LB Pharmaceuticals Inc (LBRX) at Outperform

Tue, 07 Jul 2026 05:32:33 -0400

Wolfe Research analyst Rudy Li initiates coverage on LB Pharmaceuticals Inc (NASDAQ: LBRX) with a Outperform rating and a price target of $45.00.

LB Pharmaceuticals names Christopher Zergebel as SVP of clinical ops

Tue, 30 Jun 2026 08:02:07 -0400

LB Pharmaceuticals Inc. (Nasdaq: LBRX) has appointed Christopher Zergebel as Senior Vice President of Clinical Operations, according to a press release from the biopharmaceutical company.

Zergebel brings more than 25 years of global development operations experience. He previously served as Vice President of Development Operations at Cellectis Biologics, where he led global clinical development strategy and operations from early-stage through post-approval trials. He holds a B.A. in Biology from Boston University.

The appointment comes as LB Pharmaceuticals advances multiple clinical programs for its lead candidate, LB-102. The company currently has a Phase 3 trial in schizophrenia and a Phase 2 trial in

LB Pharmaceuticals names Christopher Zergebel as SVP of clinical ops

Tue, 30 Jun 2026 08:02:07 -0400

LB Pharmaceuticals Inc. (Nasdaq: LBRX) has appointed Christopher Zergebel as Senior Vice President of Clinical Operations, according to a press release from the biopharmaceutical company.

The appointment comes as LB Pharmaceuticals advances multiple clinical programs for its lead candidate, LB-102. The company currently has a Phase 3 trial in schizophrenia and a Phase 2 trial in

LB Pharmaceuticals names Christopher Zergebel as SVP of clinical ops

Tue, 30 Jun 2026 08:02:07 -0400

LB Pharmaceuticals Inc. (Nasdaq: LBRX) has appointed Christopher Zergebel as Senior Vice President of Clinical Operations, according to a press release from the biopharmaceutical company.

The appointment comes as LB Pharmaceuticals advances multiple clinical programs for its lead candidate, LB-102. The company currently has a Phase 3 trial in schizophrenia and a Phase 2 trial in

LB Pharmaceuticals names Christopher Zergebel as SVP of clinical ops

Tue, 30 Jun 2026 08:02:07 -0400

LB Pharmaceuticals Inc. (Nasdaq: LBRX) has appointed Christopher Zergebel as Senior Vice President of Clinical Operations, according to a press release from the biopharmaceutical company.

The appointment comes as LB Pharmaceuticals advances multiple clinical programs for its lead candidate, LB-102. The company currently has a Phase 3 trial in schizophrenia and a Phase 2 trial in

LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations

Tue, 30 Jun 2026 08:00:00 -0400

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder, and other neuropsychiatric diseases, today announced the appointment of Christopher Zergebel as Senior Vice President, Clinical Operations.

Mr. Zergebel, a seasoned biotechnology executive with more than 25 years of global development operations experience, brings deep expertise in growing and leading cross-functional teams including clinical operations, data management, and project and portfolio management.

“We are pleased to welcome Chris